Back to Agenda
Live Oral Poster Presentations I
Session Chair(s)
Vedran Raguz
Scientific Programs Specialist
DIA, Switzerland
This session is an opportunity to hear Authors present their Posters Live, followed by a Q&A portion.
Learning Objective : The European Commission’s (EC) Pharmaceutical Strategy for Europe aimed to develop a future-proof pharmaceutical policy. This study aims to assess stakeholders' views on patient-centric policy initiatives and the prospects for patient-experience data (PED), expressed in the Pharmaceutical Strategy.
Speaker(s)
![Io Wens, MSc](/_Images/member/Generic_Image_Missing-Profile.jpg)
Towards patient-centered pharmaceutical policy-making: Stakeholders’ perspectives on the Pharmaceutical Strategy for Europe
Io Wens, MSc
KU Leuven, Belgium
PhD Researcher
Sustainable Regulatory Framework: A toolkit of regulatory processes and tools to enable patient access and foster innovation
Anna Litsiou, PhD, MBA, MSc
AstraZeneca, United Kingdom
Director - Regulatory Policy
Advancing Patient Experience Data in Healthcare Decision-Making: Multi-stakeholders’ insights on policy ways forward
Alice Vanneste, MS, MSc
KU Leuven, Belgium
PhD Student
Data science and artificial intelligence to study the drug regulatory system: current and future avenues
Marjon Pasmooij, PhD
Dutch Medicines Evaluation Board / Utrecht University, Netherlands
Head Science Department / Associate Professor of Drug Regulatory Science
![Antoine Manson, PharmD, MPharm](/_Images/member/Generic_Image_Missing-Profile.jpg)
Using AI to Accelerate Medicines Development: An Evolving EU Regulatory Landscape
Antoine Manson, PharmD, MPharm
Bayer AG, France
Regulatory Policy and Innovation Specialist
![Katelyn Rivas, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Lessons Learned: A Supplier’s Perspective on Strategies for Promoting Sustainability in the Regulatory Submissions Process
Katelyn Rivas, PhD
Synterex, Inc., United States
Regulatory Medical Writer
![Daniel Reed, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
Regulatory science considerations for cell and gene therapy in chronic diseases: cardiovascular disease as a case study
Daniel Reed, PhD
AstraZeneca, United Kingdom
Senior Regulatory Intelligence Director
Access to Medicines: Models for future Regulatory Authority and HTA body work-sharing?
Carolyn Hynes, PhD
AstraZeneca, United Kingdom
Senior Director Regulatory Intelligence
![Sevengul Car, MS, MSc](/_Images/member/Generic_Image_Missing-Profile.jpg)
Evolving Global Regulatory Landscape for Approval of Biosimilars: Current Challenges and Future Considerations
Sevengul Car, MS, MSc
KU Leuven, Belgium
PhD researcher
Have an account?